Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amicus Therapeutics establishes new facility in San Diego
According to the company, the new facility will be used to support ongoing research into new applications of the company’s platform technology. The new laboratory space was included
According to the company, the new facility will be used to support ongoing research into new applications of the company’s platform technology. The new laboratory space was included
Mr Harris was most recently vice president of US sales and global marketing at Salient Surgical Technologies (formerly TissueLink). Prior to TissueLink, Mr Harris served as national sales
The Akreos AO lens is a single-piece, foldable acrylic intraocular lens with a four-haptic design and aspheric optics designed to be aberration-free. The company expects to begin shipping
The new bill was proposed by Patrick Kennedy, the representative for Rhode Island, and includes tax incentives for research into personalized medicine. Similar to Mr Obama’s 2007 bill,
The Spot-Light Her2 CISH kit has received FDA premarket approval in July 2008, as an aid in the assessment of breast cancer patients for whom trastuzumab (Herceptin) treatment
This award provides an additional $3.65 million from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), on top
Dr Hsia was formerly senior vice president of scientific affairs at Watson Pharmaceuticals before his retirement. Dr Hsia has received a PhD in industrial and physical pharmacy from
The study is a randomized, multi-center, investigator-masked, timolol- and placebo-controlled evaluation of the safety and efficacy of OT-730 in reducing the intraocular pressure in subjects with ocular hypertension
The Phase III Roche-sponsored AVAiL study in patients with previously untreated, advanced non-small cell lung cancer (NSCLC), has confirmed that Avastin (bevacizumab) combined with gemcitabine-cisplatin chemotherapy offers a
Sequenom said that these newly acquired rights expand the company’s existing, broad intellectual property (IP) portfolio of noninvasive prenatal diagnostic methods using fetal nucleic acids obtained from a